Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial

Authors

Sara A Hurvitz, University of California, Los Angeles
Ron Bose, Washington University School of Medicine in St. Louis
et al

Journal

Oncologist

Publication Date

8-1-2021

Volume

26

Issue

8

First Page

e1327

Last Page

e1338

Document Type

Open Access Publication

DOI

10.1002/onco.13830

Rights and Permissions

Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist. 2021 Aug;26(8):e1327-e1338. doi: 10.1002/onco.13830 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Hurvitz, Sara A; Bose, Ron; and et al, "Efficacy of neratinib plus capecitabine in the subgroup of patients with central nervous system involvement from the NALA trial." Oncologist. 26, 8. e1327 - e1338. (2021).
https://digitalcommons.wustl.edu/oa_4/298